Low Molecular Weight Mannogalactofucans Derived from Undaria pinnatifida Induce Apoptotic Death of Human Prostate Cancer Cells In Vitro and In Vivo
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
30159630
DOI
10.1007/s10126-018-9851-3
PII: 10.1007/s10126-018-9851-3
Knihovny.cz E-zdroje
- Klíčová slova
- Fucoidan, Low molecular weight mannogalactofucans, Prostate cancer, Undaria pinnatifida,
- MeSH
- apoptóza účinky léků MeSH
- beta-katenin metabolismus MeSH
- kinasa glykogensynthasy 3beta metabolismus MeSH
- kontrolní body buněčného cyklu účinky léků MeSH
- lidé MeSH
- membránový potenciál mitochondrií účinky léků MeSH
- messenger RNA genetika MeSH
- molekulová hmotnost MeSH
- myši MeSH
- nádory prostaty farmakoterapie metabolismus MeSH
- polysacharidy chemie farmakologie terapeutické užití MeSH
- Undaria chemie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- beta-katenin MeSH
- fucoidan MeSH Prohlížeč
- kinasa glykogensynthasy 3beta MeSH
- messenger RNA MeSH
- polysacharidy MeSH
Low molecular weight mannogalactofucans (LMMGFs) prepared by enzymatic degradation of high molecular weight Undaria galactofucan (MF) were evaluated for their anti-cancer effects against human prostate cancer. Correlation NMR and linkage analyses confirmed that LMMGFs consist mainly of α-fucose and β-galactose units: α-fucose units are 1,3-linked; β-galactose units are terminal, 1,3- and/or 1,6-linked; both sugars are partially sulphated, fucose at positions O-2 and/or O-4 and galactose at O-3. Mannose residue, as a minor sugar, presents as the 1,4-linked terminal units. LMMGFs more significantly induced cell cycle arrest at the G0/G1 phase and cell death via suppression of the Akt/GSK-3β/β-catenin pathway than MF in human PC-3 prostate cancer cells. LMMGFs upregulated mRNA expression of death receptor-5 (DR-5), the ratio of Bax to Bcl-2, the cleavage of caspases and PARP, the depolarisation of mitochondrial membrane potential, and ROS generation. LMMGFs (200-400 mg/kg) effectively reduced both tumour volume and size in a xenografted mouse model. These results demonstrated that LMMGFs attenuate the growth of human prostate cancer cells both in vitro and in vivo, suggesting that LMMGFs can be used as a potent functional ingredient in health-beneficial foods or as a therapeutic agent to prevent or treat androgen-independent human prostate cancer. Graphical Abstract.
Biocenter Gyeonggido Business and Science Accelerator Suwon Gyeonggi do 16229 South Korea
Department of Biotechnology The Catholic University of Korea Bucheon Gyeonggi do 14662 South Korea
Zobrazit více v PubMed
Eur J Cancer. 2011 Aug;47(12):1890-907 PubMed
Cell Mol Life Sci. 2007 Aug;64(15):1930-44 PubMed
Oncotarget. 2014 Sep 15;5(17):7870-85 PubMed
J Biomed Mater Res A. 2008 Dec 1;87(3):666-75 PubMed
Urol Clin North Am. 1996 Nov;23(4):605-16 PubMed
Int J Biol Macromol. 2017 Oct;103:286-293 PubMed
Biosci Biotechnol Biochem. 2013;77(2):235-42 PubMed
Cancer Lett. 2008 Dec 8;272(1):91-101 PubMed
Carbohydr Res. 2002 Apr 17;337(8):719-30 PubMed
Nutr Cancer. 2013;65(3):460-8 PubMed
Urology. 1997 Mar;49(3A Suppl):5-15 PubMed
Arch Pharm Res. 2010 Jan;33(1):125-31 PubMed
J Biochem. 1964 Feb;55:205-8 PubMed
Mar Drugs. 2015 Jul 16;13(7):4398-417 PubMed
Neoplasia. 2001 Nov-Dec;3(6):535-46 PubMed
Mar Drugs. 2013 Aug 19;11(8):2982-99 PubMed
PLoS One. 2011;6(11):e27441 PubMed
Acta Biochim Biophys Sin (Shanghai). 2015 Nov;47(11):925-31 PubMed
Life Sci. 2014 Dec 5;119(1-2):47-55 PubMed
J Cell Biochem. 2008 May 1;104(1):82-95 PubMed
Science. 1997 Feb 21;275(5303):1132-6 PubMed
J Microbiol Biotechnol. 2008 Apr;18(4):616-23 PubMed
Carbohydr Polym. 2014 Oct 13;111:633-44 PubMed
Genes Dev. 2004 Apr 15;18(8):851-5 PubMed
Mar Drugs. 2014 Jan 28;12(2):851-70 PubMed
J Biol Chem. 2006 Dec 8;281(49):37844-52 PubMed
Chem Res Toxicol. 1992 Mar-Apr;5(2):227-31 PubMed
Planta Med. 2006 Dec;72(15):1415-7 PubMed
J Pharmacol Exp Ther. 2003 Apr;305(1):24-30 PubMed
Mol Pharmacol. 2003 Sep;64(3):696-702 PubMed
Mar Biotechnol (NY). 2015 Dec;17(6):718-35 PubMed
Carbohydr Res. 2004 Feb 25;339(3):511-7 PubMed
Prostate. 2004 Sep 15;61(1):35-49 PubMed
Mar Drugs. 2016 Jul 07;14(7): PubMed
Mol Cell Biol Res Commun. 2000 Aug;4(2):67-75 PubMed
Exp Cell Res. 2010 Jan 1;316(1):1-11 PubMed
Cancer. 2004 Dec 15;101(12):2881-91 PubMed
PLoS One. 2012;7(8):e43483 PubMed
Nat Rev Cancer. 2002 Sep;2(9):647-56 PubMed
Carcinogenesis. 2013 Apr;34(4):874-84 PubMed
Cancer Res. 2007 Jul 15;67(14):6925-35 PubMed
Toxicol Pathol. 2007 Jun;35(4):495-516 PubMed
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 PubMed
J Mol Signal. 2007 Oct 04;2:10 PubMed
Nat Rev Cancer. 2009 Jun;9(6):400-14 PubMed
Am J Hematol. 2005 Jan;78(1):7-14 PubMed
Mar Drugs. 2011;9(10):1731-60 PubMed
Prostate. 2005 Feb 1;62(2):165-86 PubMed
Biosci Biotechnol Biochem. 1999;63(10):1813-5 PubMed
Int J Biol Macromol. 2008 Dec;43(5):433-7 PubMed
